US Edition
AROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met
The trial enrolled up to 150 patients across U.S. sites and showed more diabetic foot ulcers healed with Symphony versus standard care during the 12-week treatment period.
- Aroa Biosurgery announced Sunday that its randomised controlled trial for Symphony met the primary endpoint in treating chronic diabetic foot ulcers.
- This prospective, multi-centre trial evaluated the safety and performance of Symphony, a Cellular, Acellular and Matrix-like Product designed for Wagner grade 1 and 2 non-healing diabetic foot ulcers.
- Researchers recruited up to 150 patients across United States sites, randomising participants to receive either Symphony or standard of care dressings weekly for up to 12 weeks.
- Chief Executive Officer Brian Ward stated the results represent a "crucial step" in building clinical evidence required to support future clinical adoption and reimbursement policies.
- The Company expects to publish full study results in the coming months, which it believes will further validate Symphony's clinical efficacy for managing complex wounds.
26 Articles
26 Articles
The Times of Northwest Indiana
AROA Biosurgery Completes Randomised Controlled Trial for Symphony™; Preliminary Read-Out indicates Primary Endpoint Met
AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint.
Aroa’s Symphony hits the right notes in diabetic foot ulcer trial
Aroa’s Symphony randomised controlled trial in diabetic foot ulcers completed Preliminary findings indicate the trial met its primary endpoint, outperforming standard of care Publication of the study expected to support Symphony’s clinical adoption and future US reimbursement requirements Special Report: Aroa Biosurgery has reached a key milestone, with its Symphony randomised controlled trial in diabetic foot ulcers (DFUs) now complete and p…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
